Incidence and Risk Factors of Postoperative Urinary Retention After Thyroidectomy: A Retrospective Cohort Study
Abstract
ABSTRACT Background Postoperative urinary retention (POUR) is a common complication, but its incidence and risk factors after thyroidectomy are not well‐defined. We investigated the incidence of POUR after thyroidectomy and its risk factors. Methods We conducted a retrospective review of 511 consecutive patients who underwent thyroidectomy by a single surgeon. POUR was defined as the inability to void within 6 h of the last preoperative void performed immediately prior to transfer to the operating room, with bladder volume > 500 mL requiring catheterization. Univariable and multivariable logistic regressions were performed separately for male and female. Results Among 511 patients (368 females, 143 males; mean age 49.6 years), 412 (80.6%) underwent lobectomy, 71 (13.9%) total thyroidectomy without lateral neck dissection, and 28 (5.5%) total thyroidectomy with lateral neck dissection. Surgical access was open in 333 (65.2%), transoral robotic in 158 (30.9%), and transoral endoscopic in 20 (3.9%). Overall, 68 patients (13.3%) developed POUR. In males, independent predictors were benign prostatic hyperplasia (BPH) (adjusted odds ratio [aOR] 7.890; 95% confidence interval [CI], 1.814–34.318; p = 0.006) and body mass index (BMI) < 25 kg/m2 (≥ 25 kg/m2 aOR 0.245; 95% CI, 0.066–0.909; p = 0.036; reference < 25 kg/m2), BMI < 25 kg/m2 (≥ 25 kg/m2 aOR 0.465; 95% CI, 0.228–0.947; p = 0.035; reference < 25 kg/m2), and operative time ≥ 60 min (aOR 1.939; 95% CI, 1.014–3.709; p = 0.045).…
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.